Inventiva (IVA)
NASDAQ:IVA
IVA Stock Chart & Stats
$5.51
-$0.02(-0.90%)
At close: 4:00 PM EST
$5.51
-$0.02(-0.90%)
Day’s Range― - ―
52-Week Range$2.85 - $7.98
Previous CloseN/A
Volume917.00
Average Volume (3M)99.38K
Market Cap
$1.08B
Enterprise Value$566.85M
Total Cash (Recent Filing)$99.27M
Total Debt (Recent Filing)$59.40M
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Sep 23, 2026EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding207,707,470
10 Day Avg. Volume175,727
30 Day Avg. Volume99,378
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-25.46
Price to Sales (P/S)164.91
P/FCF Ratio-7.30
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue131.64
Enterprise Value/Gross Profit358.61
Enterprise Value/Ebitda-2.33
Forecast
1Y Price Target
$16.67Price Target Upside202.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$3.95M
Bulls Say, Bears Say
Bulls Say
External Validation And Valuation UpsideRecent takeover activity among peers and positive external conjugate data provide industry validation and suggest the company may be undervalued relative to comparable assets, supporting potential investor upside if clinical goals are met.
Physician Adoption PotentialSurveyed physicians indicate willingness to prescribe the drug for patients who cannot tolerate existing therapies, suggesting steady uptake among specific patient subgroups.
Therapeutic Profile And Commercial PotentialAn oral, balanced PPAR mechanism that reduces liver fibrosis while improving metabolic measures supports attractive commercial potential in a large undiagnosed and untreated patient population if efficacy is confirmed.
Bears Say
Clinical Trial Statistical Risk And CompetitionA conservatively powered trial design that anticipates a strong placebo response raises the bar for demonstrating benefit and, together with emerging competitors pursuing similar receptor strategies, heightens clinical and commercial risk.
Financial Risk And DilutionRising operating losses and higher selling and general expenses, combined with limited cash relative to current spending, increase the likelihood of dilutive financing that could depress the stock.
Safety And Tolerability ConcernsTreatment-related edema and weight gain observed in trials could limit physician prescribing and narrow the addressable market, weighing on commercial uptake.
Inventiva News
IVA FAQ
What was Inventiva’s price range in the past 12 months?
Inventiva lowest stock price was $2.85 and its highest was $7.98 in the past 12 months.
What is Inventiva’s market cap?
Inventiva’s market cap is $1.08B.
When is Inventiva’s upcoming earnings report date?
Inventiva’s upcoming earnings report date is Sep 23, 2026 which is in 161 days.
How were Inventiva’s earnings last quarter?
Inventiva released its earnings results on Mar 30, 2026. The company reported -$1.067 earnings per share for the quarter, missing the consensus estimate of -$0.279 by -$0.788.
Is Inventiva overvalued?
According to Wall Street analysts Inventiva’s price is currently Undervalued.
Does Inventiva pay dividends?
Inventiva does not currently pay dividends.
What is Inventiva’s EPS estimate?
Inventiva’s EPS estimate is -0.42.
How many shares outstanding does Inventiva have?
Inventiva has 207,707,470 shares outstanding.
What happened to Inventiva’s price movement after its last earnings report?
Inventiva reported an EPS of -$1.067 in its last earnings report, missing expectations of -$0.279. Following the earnings report the stock price went up 1.277%.
Which hedge fund is a major shareholder of Inventiva?
Currently, no hedge funds are holding shares in IVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inventiva Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (202.54% Upside)
$16.67 (202.54% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.43%
12-Months-Change
Fundamentals
Return on Equity
536.36%
Trailing 12-Months
Asset Growth
399.59%
Trailing 12-Months
Company Description
Inventiva
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
IVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a constructive and execution-focused picture: major operational milestones were achieved (NATiV3 enrollment completion, >1,000 patients, clear Q4 2026 readout target), a solid near-term cash position (EUR 230.9M), conservative powering (>90%) and organizational strengthening for regulatory/commercial readiness. Key risks remain—funding beyond the stated runway depends on tranche/warrant mechanics or future financing, tolerability (weight gain/fluid retention) is a known class risk to be monitored, endpoints have inherent variability, and competition is active. On balance the call emphasized progress, readiness and a clear pathway to a potentially pivotal readout while acknowledging material clinical and financing dependencies.View all IVA earnings summariesIVA Stock 12 Month Forecast
Average Price Target
$16.67
▲(202.54% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Urogen Pharma
―
Maravai Lifesciences Holdings
―
MBX Biosciences, Inc.
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
17.46% Other Institutional Investors
82.42% Public Companies and Individual Investors
Options Prices
Currently, No data available
---